<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657084</url>
  </required_header>
  <id_info>
    <org_study_id>2012051485</org_study_id>
    <nct_id>NCT01657084</nct_id>
  </id_info>
  <brief_title>Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask</brief_title>
  <acronym>EpiCapno</acronym>
  <official_title>Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By enabling a partial rebreathing of expired gas, a moderate respiratory acidosis is
      induced, without causing hypoxia in the patient.

      Based on the scientific literature on the subject, the study hypothesis is that the fall in
      body pH will be able to stop and/or prevent epileptic brain activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Length of epileptic seizure (subgroup 1)</measure>
    <time_frame>Duration of mask treatment during acute seizures: approx. 3 minutes from start of mask treatment until end of seizure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of epileptic seizure with treatment mask vs. dummy mask</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of epileptic paroxysms (subgroups 2 and 3)</measure>
    <time_frame>Duration of mask treatment: 45 minutes (group 2) or 10 minutes (group 3) during which patient is monitored with EEG</time_frame>
    <safety_issue>No</safety_issue>
    <description>Frequency of epileptic paroxysms as measured by EEG, treatment mask vs. dummy mask</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation during mask treatment</measure>
    <time_frame>Duration of mask treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measures oxygen saturation using a pulse oximeter during mask treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Tonic-clonic seizures</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generalized Paroxysms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CDA Mask</intervention_name>
    <description>The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.</description>
    <arm_group_label>Tonic-clonic seizures</arm_group_label>
    <arm_group_label>Generalized Paroxysms</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dummy mask</intervention_name>
    <description>The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases</description>
    <arm_group_label>Tonic-clonic seizures</arm_group_label>
    <arm_group_label>Generalized Paroxysms</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Epilepsy

          -  18-80 years

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jakob Christensen, M.D., Ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jakob Christensen, MD, PhD</last_name>
    <phone>+45 60865899</phone>
    <email>JAKOB@FARM.AU.DK</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Troels Johansen, M.Sc.Eng.</last_name>
    <phone>+ 40977313</phone>
    <email>troels.johansen@ki.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Epilepsy Hospital Filadelfia</name>
      <address>
        <city>Dianalund</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandor Beniczky, MD, PhD</last_name>
      <email>sbz@filadelfia.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>January 15, 2015</lastchanged_date>
  <firstreceived_date>August 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
